Mechanism, clinical consequences, and management of dyslipidemia in children with nephrotic syndrome

• Main Author: Hee Sun Baek (Author)
• Format: Book
• Published: Korean Society of Pediatric Nephrology, 2022-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 2384-0242; 2384-0250; 10.3339/ckd.22.020
• Keywords: child; dyslipidemias; nephrotic syndrome; Internal medicine; RC31-1245; Pediatrics; RJ1-570
• Source: Childhood Kidney Diseases, Vol 26, Iss 1, Pp 25-30 (2022)

Dyslipidemia in nephrotic syndrome (NS) is often characterized by marked increases in the levels of total cholesterol, triglycerides, low-density lipoprotein cholesterol, and other lipoproteins, such as very low-density lipoprotein, intermediate-density lipoprotein, and lipoprotein(a). It has been suggested that impaired catabolism of lipoproteins and cholesterol is mainly due to decreased lipoprotein lipase and hepatic lipase activity, and increased biosynthesis of lipoproteins in the liver. The management strategies for dyslipidemia in patients with NS consist of lifestyle modification, lipid-lowering agents represented by statins, second-line agents such as fibrates and bile acid sequestrants, and lipid apheresis. Compared with dyslipidemia in adult NS patients, whose risks of atherosclerotic disease and progressive renal injury are considered high, clinical data on dyslipidemia in pediatric NS patients are limited. Therefore, it is necessary to pay more attention to the evaluation and management of dyslipidemia in pediatric patients with NS in clinical practice.